Welcome to our dedicated page for Foghorn Therapeutics news (Ticker: FHTX), a resource for investors and traders seeking the latest updates and insights on Foghorn Therapeutics stock.
Foghorn Therapeutics Inc. (FHTX) is a clinical-stage biopharmaceutical pioneer developing precision medicines targeting chromatin regulation in oncology. This news hub provides investors and industry professionals with essential updates on the company's therapeutic pipeline, strategic collaborations, and clinical milestones.
Access timely reports on FHTX's innovative programs including FHD-286 (hematologic cancers), FHD-609 (synovial sarcoma), and FHD-909 (non-small cell lung cancer). Stay informed about regulatory developments, partnership announcements, and scientific presentations related to their Gene Traffic Control platform.
Our curated news collection serves as a comprehensive resource for tracking progress across preclinical studies, clinical trials, and business operations. Bookmark this centralized source for verified updates on Foghorn's novel protein degraders and chromatin-targeting therapies.
Foghorn Therapeutics Inc. (Nasdaq: FHTX) has paused enrollment in its FHD-609 clinical study targeting synovial sarcoma and SMARCB1-deleted tumors after a serious QTc prolongation event occurred in a patient at the second highest dose. The dose escalation phase is completed, and a maximum tolerated dose has been identified. The FDA has placed the study on a partial clinical hold but allows current patients to continue treatment. The company is not planning to pursue a dose expansion study independently at this time. The update highlights Foghorn's commitment to patient safety and regulatory compliance.
Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced the presentation of preclinical data for its protein degrader programs at the 2023 AACR Annual Meeting from April 14–19 in Orlando, FL. Highlights include findings on FHD-286, a BRG1/BRM inhibitor, demonstrating potential efficacy as both a monotherapy and in combination treatments for acute myeloid leukemia (AML). FHD-286 has exhibited strong anti-tumor activity across various malignancies. The company will also present data on Selective EP300 and Selective CBP programs, targeting specific cancer mutations with significant unmet medical needs. Presentations will occur on key dates throughout the meeting, showcasing innovative approaches in cancer therapies.
Foghorn Therapeutics Inc. (Nasdaq: FHTX) has announced oral presentations at the 18th Annual Drug Discovery Chemistry Meeting from April 10-13, 2023, in San Diego, CA. The company will share preclinical data on FHD-609, a first-in-class protein degrader of BRD9, currently undergoing Phase 1 clinical trials for synovial sarcoma and SMARCB1-loss tumors. Initial safety and efficacy data is expected mid-2023. Additionally, Foghorn will showcase its innovative platform that targets transcription factors, illustrating how it identifies protein interactions driving disease. The presentation titled Targeting Transcription Factor – BAF Interactions in Cancer will occur on April 13, alongside a presentation on FHD-609's discovery. This meeting emphasizes Foghorn's commitment to developing therapies addressing critical unmet needs in oncology.
Foghorn Therapeutics (Nasdaq: FHTX) provided a corporate update highlighting ongoing Phase 1 studies for drug candidates FHD-286 and FHD-609 in metastatic uveal melanoma and synovial sarcoma, respectively, with initial efficacy data expected in mid-2023. The company has a robust preclinical pipeline with potential for six new IND applications over the next four years. As of December 31, 2022, Foghorn reported $345.8 million in cash, ensuring financial stability until at least the second half of 2025. Significant revenue growth was noted, with collaboration revenues increasing to $19.2 million in 2022, up from $1.3 million in 2021, although net losses also increased to $108.9 million.
Foghorn Therapeutics Inc. (Nasdaq: FHTX) will present at Cowen’s 43rd Annual Health Care Conference from March 6-8, 2023, in Boston, MA. The company is focused on developing a new class of medicines through its Gene Traffic Control® platform, primarily targeting oncology. CEO Adrian Gottschalk will discuss their leukemia panel on March 8 at 12:50 p.m. ET. A webcast of the panel will be available on the company's website for up to 30 days. Foghorn's innovative approach aims to alter gene expression to treat serious diseases, enhancing the lives of many patients.
Foghorn Therapeutics (FHTX) announced its 2023 strategic goals, emphasizing the advancement of its clinical pipeline, including the Phase 1 studies of FHD-286 for metastatic uveal melanoma and FHD-609 for synovial sarcoma. Initial efficacy and safety data for both studies are expected in mid-2023. The company anticipates submitting at least six new INDs over the next four years, supported by a strong cash position of $373.5 million, projected to last into the second half of 2025.
Foghorn Therapeutics (FHTX) announced that new preclinical data for its FHD-286 program will be presented at the 64th Annual ASH Meeting, taking place from December 10-12, 2022, in New Orleans. The data suggest potential efficacy in treating acute myeloid leukemia (AML) using FHD-286, an allosteric inhibitor of BRG1 and BRM, with demonstrated anti-tumor activity across various malignancies. While the Phase 1 trial in uveal melanoma is ongoing, the AML trial is currently on clinical hold. The presentation will occur on December 12, 2022, and the poster will be available on their website after the event.
Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced that CEO Adrian Gottschalk will participate in the virtual Evercore ISI HealthCONx Conference on November 30, 2022, at 2:40 p.m. ET. The company focuses on gene expression treatments for serious diseases, particularly in oncology, using its Gene Traffic Control platform. The event will include a fireside chat, and a webcast will be available on the company's website for 90 days. Foghorn is developing innovative medicines that target chromatin regulatory systems.
Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced preclinical data for FHD-609, a first-in-class BRD9 degrader, at the 2022 CTOS Annual Meeting, set for November 16–19, 2022, in Vancouver, Canada.
The presentation on November 17, 2022, will detail FHD-609's potential in treating synovial sarcoma, a rare, aggressive cancer. With approximately 800 new cases annually in the U.S., current treatments are limited. FHD-609's preclinical studies show promise in inhibiting tumor growth. For further data, access the poster post-presentation via the company's website.
Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced new preclinical data for its FHD-286 program during the SITC 37th Annual Meeting held from November 8-12, 2022. The data highlights the efficacy of FHD-286, a BRG1/BRM inhibitor, in combination with an anti-PD-1 antibody, showcasing improved survival benefits in preclinical models. FHD-286 is in Phase 1 trials targeting metastatic uveal melanoma and acute myelogenous leukemia, although the AML and myelodysplastic syndrome trial is currently on clinical hold. The poster presentation is scheduled for November 11, 2022.
